Article Text

PDF
Drug sensitivity testing platforms for gastric cancer diagnostics
  1. Vianne Lau1,
  2. Andrea Li-Ann Wong2,
  3. Christopher Ng3,4,
  4. Yingting Mok5,
  5. Manikandan Lakshmanan6,
  6. Benedict Yan3,4
  1. 1Department of Gastroenterology Monash University, Melbourne, Australia
  2. 2Department of Haematology and Oncology, National University Health System, Singapore, Singapore
  3. 3Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
  4. 4Department of Laboratory Medicine, Molecular Diagnosis Centre, National University Hospital, National University Health System, Singapore, Singapore
  5. 5Department of Pathology, National University Hospital, National University Health System, Singapore, Singapore
  6. 6Mouse Models for Human Cancer Unit, Institute of Molecular and Cell Biology, Singapore, Singapore
  1. Correspondence to Dr Benedict Yan, Department of Laboratory Medicine, Molecular Diagnosis Centre, National University Hospital, National University Health System, Singapore 119074, Singapore; tranceblues{at}gmail.com

Abstract

Gastric cancer diagnostics has traditionally been histomorphological and primarily the domain of surgical pathologists. Although there is an increasing usage of molecular and genomic techniques for clinical diagnostics, there is an emerging field of personalised drug sensitivity testing. In this review, we describe the various personalised drug sensitivity testing platforms and discuss the challenges facing clinical adoption of these assays for gastric cancer.

  • GASTRIC CANCER
  • CHEMOTHERAPY
  • CIRCULATING TUMOUR CELLS

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.